Hydrodynamic characteristics of prosthetic heart valves Cardiamed



Similar documents
Dysfunction of aortic valve prostheses

Heart valve repair and replacement

I know my value. Be an active part of your anticoagulation therapy with INR self-monitoring

Mitral valve repair current Status and the modern Sternotomy

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Updates to the Alberta Human Services Drug Benefit Supplement

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

5. Management of rheumatic heart disease

Anticoagulant therapy

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

WATCHMAN Left Atrial Appendage Closure Device

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Cardiology Update 2014

Lecture 5 Hemodynamics. Description of fluid flow. The equation of continuity

The author has no disclosures

Commissioning effective anticoagulation services for the future

Real-Time 3-Dimensional Transesophageal Echocardiography in the Evaluation of Post-Operative Mitral Annuloplasty Ring and Prosthetic Valve Dehiscence

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Contents. Microfluidics - Jens Ducrée Physics: Fluid Dynamics 1

Press conference: Rheumatic Heart Disease a forgotten but devastating disease

Treatments to Restore Normal Rhythm

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

Dorset Cardiac Centre

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Dental Work and the Risk of Bacterial Endocarditis

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.

National Patient Safety Goals Effective January 1, 2015

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation

The Effect of Daily Low-Dose Vitamin K Bottle Refraction

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Reducing Adverse Drug Events With Anti Coagulation Clinics. McFarland Clinic. McFarland Protime Clinic 09/05/12

Warfarin therapy for stroke patients with atrial fibrillation

National Patient Safety Goals Effective January 1, 2015

What You Need to KnowWhen Taking Anticoagulation Medicine

Fellow TEE Review Workshop Hemodynamic Calculations Director, Intraoperative TEE Program. Johns Hopkins School of Medicine

Antiplatelet and Antithrombotics From clinical trials to guidelines

How To Treat Heart Valve Disease

Order and/or Delegated Procedure :

17 Endocarditis. Infective endocarditis

Note: The left and right sides of the heart must pump exactly the same volume of blood when averaged over a period of time

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

CorCap Cardiac Support Device Patient Information Booklet

Educational Goals & Objectives

STROKE PREVENTION IN ATRIAL FIBRILLATION

Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients

WAITING TIME REDUCTION IN OUTPATIENT SERVICES - ANALOGY TO HEART FAILURE THERAPY

How diagnostics can help alleviate healthcare cost burden. James Creeden, Chief Medical Officer Roche Professional Diagnostics

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Confirmed Deep Vein Thrombosis (DVT)

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

AgoraLink Agora for Life Science Technologies Linköpings Universitet Kurs i Fysiologisk mätteknik Biofluidflöden

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Department of Transportation (DOT) Changes PHYSICAL EXAMINATION CHANGES

Clinical Practice Guideline for Anticoagulation Management

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

Anticoagulation at the end of life. Rhona Maclean

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

New Anticoagulants: When and Why Should I Use Them? Disclosures

Atrial Fibrillation (AF) Explained

The Björk-Shiley Convexo-Concave Heart Valve Experience from the Perspective of the Supervisory Panel

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults

Knee Replacement Surgery and Blood Clots What You Need To Know

ELSO GUIDELINES FOR TRAINING AND CONTINUING EDUCATION OF ECMO SPECIALISTS

Living. with. Warfarin

Magnetic Resonance Quantitative Analysis. MRV MR Flow. Reliable analysis of heart and peripheral arteries in the clinical workflow

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April Reference: NHSCB/A09/PS/b

The St Jude Medical Trifecta aortic pericardial valve: Results from a global, multicenter, prospective clinical study

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

FLUID FLOW STREAMLINE LAMINAR FLOW TURBULENT FLOW REYNOLDS NUMBER

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

How To Teach An Integrated Ultrasound

What to Know About. Atrial Fibrillation

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Listen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need

Dabigatran (Pradaxa) Guidelines

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions

Summary and general discussion

What Are Arrhythmias?

How To Take Xarelto

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

How To Understand How The Brain Can Be Affected By Cardiac Problems

5. Diagnosis and management of rheumatic heart disease

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

HISTORY. Questions: 1. What diagnosis is suggested by this history? 2. How do you explain her symptoms during pregnancy?

The Role of the Newer Anticoagulants

Transcription:

Hydrodynamic characteristics of prosthetic heart valves Cardiamed Hydrodynamic characteristics of blood flow passing through a prosthetic heart valve have profound effect on the activation of thrombus formation processes on it as well as on trauma of formed elements of blood. During laminar stream flow similar to physiological blood flow through cardiovascular system there is no trauma of formed elements of blood, i.e. of erythrocytes and thrombocytes (Fig.1) The flow stresses, occurring in the areas of separation of blood flow from the surface of prosthetic valve and in the areas of turbulence formation, can cause trauma of formed elements of blood. (Fig.2) This can lead to increased hemolysis or activation of thrombocytes. In areas adjacent to prosthetic valve, where stagnation zones in blood flow occur, there are suitable conditions for adhesion of thrombocytes and activation of thrombus formation process. (Fig.3). In order to eliminate the possibility of stable localization of blood stagnation zones, the leaflets of Cardiamed valve rotate around the central axis of the valve housing during its performance (Fig.4). The continuous change of orientation of valve leaflets triggers the change in the localization of blood stagnation zones, thus reducing the risk of thrombus formation.

In order to ensure a laminar blood flow and reduce flow stresses, the leaflets of Cardiamed valve in contrast with the leaflets of the known prosthetic valves from other valve manufacturers are not flat but have a special curved shape. This allows to improve flow structure and obtain more homogeneous distribution of velocities within flow. Fig.5 shows relative distribution of local velocity value V within flow passing through the valves with respect to mean flow velocity V o for the valve having common flat leaflets and for Cardiamed valve having curved leaflets. (The studies were carried out at the State Polytechnic University of St. Petersburg) The special aerodynamic shape of Cardiamed valve leaflets ensures the generation of a practically laminar blood flow passing through all valve orifice openings when the valve is in the open position. Fig.6 shows streamlines and velocity profile of blood flow passing through Cardiamed valve, visualized by hydrogen bubble method. The aerodynamic shape of Cardiamed valve leaflets not only generate a laminar blood flow, but also speeds up valve opening and closure. Fig.7 shows results of comparison test for modern prosthetic heart valves using pulse duplicator with the aim to determine the time of valve closure at various cycle frequencies. One of the most effective methods for reducing the risk of thrombus formation is to use regurgitant blood flow for proper washing of dangerous zones. In order to implement this method for Cardiamed valve, the valve has special slots in the area of hinge mechanism without any casual clearances between leaflets and valve housing in the closed position. Due to this local jets of blood, wh

ich wash hinge mechanism, are formed (Fig.8). While passing through the valve these jets move tangent to the valve housing. As a result these jets force blood rotate inside heart chambers, thus reducing the risk of formation of stagnation zones (Fig.9). The studies confirmed that the trauma of erythrocytes does not occur in the regurgitant jets and that regurgitant volume of blood passing through Cardiamed valves does not differ much from the corresponding values of modern heart valve prostheses.

Hemodynamic characteristics of prosthetic heart valves Cardiamed Hydrodynamic characteristics of prosthetic heart valves Cardiamed are in compliance with the current requirements of cardiac surgery. The numerous studies of pressure gradients of Cardiamed valves in vivo with the use of ultrasonic instruments confirm that the gradients are similar to those of modern mechanical prostheses (Fig.11 Fig.13). The physical status of the most patients who received Cardiamed valves correspond to functional class II (NYHA) (Fig.14, 15). Clinical investigations of prosthetic heart valves Cardiamed The most extensive clinical investigation was conducted at the Research Institute for Transplantology and Artificial Organs (Moscow) with more than 1500 implants of prosthetic heart valve CardiaMed during a period of 10 years. The statistically processed clinical data is given in Figs. 16-29.

One feature of clinical use of CardiaMed valve was the prescription of the anticoagulant therapy with fenilin, an anticoagulant of indirect action, to most patients. Warfarin was prescribed in small number of cases because of difficulty of selecting the right dosage (patients were at higher risk of thromboembolic complications). Another feature of patient follow-up was a non-standard control of blood clotting. Control of PTI was used at the hematological laboratories and only in few cases they used INR control. Although there were no appropriate control for the level of blood clotting, it could be claimed that the level of blood clotting in patients was sufficiently high because there were no incidence of hemorrhagic complications. Despite this the level of

thromboembolic complications was sufficiently low, and that fact confirms good thromboresistance characteristics of the prosthesis The frequency of valve-related complications. Prosthetic heart valves CardiaMed (2000 patients for six-year follow-up period). Complications Thrombosis of prosthesis Thromboembolis m Prosthetic valve endocarditis Haemmorrhogic complications Aortic prostheses, % patient-years Mitral prostheses, % patient-years Total % patientyear 0,22 0,14 0,17 0,99 1.09 1,05 0,33 0,07 0,17 0,0 0,0 0,0